Free Trial
NYSE:ANRO

Alto Neuroscience (ANRO) Stock Price, News & Analysis

Alto Neuroscience logo
$3.06 -0.01 (-0.33%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$3.06 0.00 (-0.16%)
As of 08/1/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alto Neuroscience Stock (NYSE:ANRO)

Key Stats

Today's Range
$3.01
$3.12
50-Day Range
$2.21
$3.11
52-Week Range
$1.60
$15.04
Volume
220,948 shs
Average Volume
118,220 shs
Market Capitalization
$82.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

Alto Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

ANRO MarketRank™: 

Alto Neuroscience scored higher than 34% of companies evaluated by MarketBeat, and ranked 704th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alto Neuroscience has only been the subject of 2 research reports in the past 90 days.

  • Read more about Alto Neuroscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alto Neuroscience is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alto Neuroscience is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alto Neuroscience has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Alto Neuroscience's valuation and earnings.
  • Percentage of Shares Shorted

    9.54% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 1.99%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alto Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Alto Neuroscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.54% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 1.99%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alto Neuroscience has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 24 news articles for Alto Neuroscience this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Alto Neuroscience's insider trading history.
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

ANRO Stock News Headlines

Jeff Bezos Launches "ChatGPT Killer"?
Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.
See More Headlines

ANRO Stock Analysis - Frequently Asked Questions

Alto Neuroscience's stock was trading at $4.23 at the start of the year. Since then, ANRO stock has decreased by 27.7% and is now trading at $3.06.

Alto Neuroscience, Inc. (NYSE:ANRO) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.06.

Alto Neuroscience (ANRO) raised $129 million in an initial public offering on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

Alto Neuroscience's top institutional shareholders include Peapod Lane Capital LLC (1.03%), Y Intercept Hong Kong Ltd (0.14%), Vanguard Personalized Indexing Management LLC (0.06%) and Ground Swell Capital LLC (0.05%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith.
View institutional ownership trends
.

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/13/2025
Today
8/02/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANRO
Previous Symbol
NYSE:ANRO
CIK
1999480
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$4.00
Potential Upside/Downside
+177.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.35%
Return on Assets
-33.86%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
22.53
Quick Ratio
22.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.62 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
27,070,000
Free Float
24,059,000
Market Cap
$82.83 million
Optionable
N/A
Beta
1.82

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:ANRO) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners